Making the compound Amanitin available for cancer therapies

Our focus is on oncology and our mission is to research and develop drugs for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

ADC Drug Development

As a drug development company we concentrate on combining the targeting properties of antibodies with the effectiveness of an ultra-potent toxin with antibody-drug conjugates (ADC), that are more effective against cancer. 

Key USP of our technology is the potential to treat multi-resistant tumors and "dormant or quiescent" tumor cells, which are regarded as a main reason for metastasis and resistance.

Read more

Latest Releases

Latest News

  • 10.03.2022
    Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117
  • 28.02.2022
    Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
  • 17.02.2022
    Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini
  • 15.02.2022
    Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma
  • 28.10.2021
    Heidelberg Pharma Participates at Various Conferences
  • More Press Releases
By Master en comunicación

Services

As a preclinical CRO we offer explorative pharmacology, drug metabolism and pharmacokinetics (DMPK) analysis and molecular biology.

Our core competence is the preclinical profiling of small molecules or biologicals destined for the treatment of cancer or inflammatory/autoimmune diseases.

Read More

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.